Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating different doses of bimekizumab in active ankylosing spondylitis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Bimekizumab (bimekizumab)

Snippet

Sponsor: UCB Biopharma S.P.R.L. | Conditions: Ankylosing Spondylitis | Phase 2 | Status: COMPLETED | Results posted: 2020-11-16